Author: Paul E Sax, MD

Section Editor: John G Bartlett, MD

Deputy Editor: Allyson Bloom, MD

Contributor Disclosures

All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jun 2018. | This topic last updated: Apr 19, 2017.

INTRODUCTION — Acute HIV infection may present as a mononucleosis type of syndrome with a
constellation of nonspecific symptoms. Without a high degree of suspicion, the diagnosis can frequently be
missed by clinicians. In some cases, early HIV infection may be asymptomatic.

The clinical manifestations and diagnosis of acute and early HIV will be reviewed here. The pathogenesis,
epidemiology, and treatment of early HIV infection are discussed separately. (See "Acute and early HIV
infection: Pathogenesis and epidemiology" and "Acute and early HIV infection: Treatment".)

DEFINITIONS — Different terms, including acute, recent, primary, and early HIV infection, have been used
in the literature to refer to variable intervals following initial infection with the virus. In this topic, we use the
term "early HIV infection" to refer to the approximate six-month period following HIV acquisition. We use the
term "acute HIV infection" to refer to symptomatic early infection, as this reflects common usage in clinical
care.

CLINICAL FEATURES

Asymptomatic infection — An estimated 10 to 60 percent of individuals with early HIV infection will not
experience symptoms [1], although the exact proportion is difficult to estimate since patients generally come
to attention because of symptoms, and thus asymptomatic infections often remain undetected. In a study of
50 acutely infected individuals who had been identified by prospective viral testing of high-risk individuals
and then were followed twice weekly, almost all had at least one reported symptom or sign during the first
four weeks of infection, but these were mainly short-lived, nonspecific, and unlikely to have brought the
individual to clinical attention outside of a study setting [2]. Subjects complained of symptoms at only 29
percent of the biweekly study visits during this period.

Time course — In patients who have acute symptomatic infection, the usual time from HIV exposure to the
development of symptoms is two to four weeks, although incubation periods as long as ten months have
been observed [3]. In one study that evaluated viral dynamics following HIV infection, the highest frequency
of symptoms and signs were observed just before peak viremia occurred, approximately two weeks after the
initial detection of viral RNA [2]. It is possible that the route of acquisition and quantity of virus inoculum
influence the time to peak viremia and the length of the incubation period.

Most symptoms associated with acute HIV infection are self-resolving; however, the severity and duration of
symptoms vary widely from patient to patient.

Signs and symptoms — A variety of symptoms and signs may be seen in association with acute
symptomatic HIV infection. This constellation of symptoms is also known as the acute retroviral syndrome.
Published series consistently report that the most common findings are fever, lymphadenopathy, sore throat,
rash, myalgia/arthralgia, diarrhea, weight loss, and headache (table 1) [2,4-8]. None of these findings is
specific for acute HIV infection, but certain features, especially prolonged duration of symptoms and the
presence of mucocutaneous ulcers, are suggestive of the diagnosis.
Beyond these more common symptoms, a wide range of other symptoms have been described in patients
with acute or early HIV infection. In one prospective study of 290 such patients, 74 (26 percent) of patients
were considered to have atypical symptomatic presentations, including opportunistic infections and central
nervous system manifestations [7].

The presence and increased severity and duration of symptoms appear to be poor prognostic factors [9-11].
As an example, in a study of 218 female sex workers with well-documented dates of HIV seroconversion
based on longitudinal screening, each additional symptom present at the time of acute infection was
associated with an increasing risk of overall mortality after a median follow-up of 4.6 years [11]. Importantly,
these data were collected on patients who did not have access to HIV therapy.

Constitutional symptoms — Fever, fatigue, and myalgias are the most common symptoms reported by
patients with acute HIV infection [2,9,12]. Fever in the range of 38 to 40ºC is present in the vast majority of
patients with symptomatic acute HIV infection [5,10,13-15]. In one study of 41 patients, the mean maximum
reported temperature was 38.9ºC [16].

Adenopathy — Nontender lymphadenopathy primarily involving the axillary, cervical, and occipital nodes
is also common. Adenopathy often develops during the second week of the illness, concomitant with the
emergence of a specific immune response to HIV. The nodes decrease in size following the acute
presentation, but a modest degree of adenopathy tends to persist [15]. Mild hepatosplenomegaly also can
occur [17].

Oropharyngeal findings — Sore throat is a frequent manifestation of acute HIV infection. The physical
examination reveals pharyngeal edema and hyperemia, usually without tonsillar enlargement or exudate
[18,19]. However, unilateral or bilateral tonsillitis has also been described [7].

Painful mucocutaneous ulceration is one of the most distinctive manifestations of acute HIV infection.
Shallow, sharply demarcated ulcers with white bases surrounded by a thin area of erythema may be found
on the oral mucosa, anus, penis, or esophagus [20]. These ulcerative lesions may reflect mucocutaneous
disease associated with acute HIV infection [15] or coincident sexually transmitted infections, such as
herpes simplex virus, syphilis, or chancroid [21]. In one study of 10 men who have sex with men (MSM) with
acute HIV infection and mucocutaneous ulceration limited to one location, the lesions occurred at a site
involved in sexual activity at the time of probable transmission. (See "Prevention of sexually transmitted
infections".)

In another study of 16 men with acute HIV infection and odynophagia, endoscopy demonstrated esophageal
ulcers 0.3 to 1.5 cm in diameter in all of the patients [22]. Tissue obtained from these ulcers in eight of the
subjects revealed virus particles by electron microscopy that were morphologically consistent with HIV; in
one patient HIV was cultured from the lesion.

Rash — A generalized rash is also a common finding in symptomatic acute HIV infection. The eruption
typically occurs 48 to 72 hours after the onset of fever and persists for five to eight days. The upper thorax,
collar region, and face are most often involved, although the scalp and extremities, including the palms and
soles, may be affected. The lesions are characteristically small (5 to 10 mm), well-circumscribed, oval or
round, pink to deeply red colored macules or maculopapules [20]. Vesicular, pustular, and urticarial
eruptions have also been reported [19,23] but are not nearly as common as a maculopapular rash. Pruritus
is unusual and only mild when present.

Histopathologic findings are nonspecific in the skin lesions, and biopsy of a skin lesion usually does not
assist in the diagnosis of acute HIV infection. The epidermis is normal and the dermis contains a sparse
lymphocytic infiltrate, mainly around vessels of the superficial plexus [17].
 Gastrointestinal symptoms — Since the gastrointestinal tract is a primary target during acute infection,
patients with acute HIV infection often complain of nausea, diarrhea, anorexia, and weight loss, averaging 5
kg. More serious gastrointestinal manifestations are rare and include pancreatitis and hepatitis [24,25].

Neurologic findings — Headache, often described as retroorbital pain exacerbated by eye movement,
frequently accompanies acute HIV infection. More serious neurologic manifestations of acute HIV infection
have also been reported but are unusual [7,26].

The first severe neurologic syndrome to be recognized was aseptic meningitis, with severe headache,
meningismus, photophobia, and a lymphocytic pleocytosis on cerebrospinal fluid (CSF) analysis [27,28]. In
a study of 41 patients with symptomatic acute HIV infection, 10 (24 percent) had symptoms and signs
suggestive of aseptic meningitis [16]. HIV was cultured from the CSF in 12 of the 24 patients who agreed to
undergo lumbar puncture (a median of 51 days after HIV seroconversion).

Rarely, a self-limited encephalopathy may accompany acute HIV infection. One report described two
patients with fever, pronounced personality changes, confusion, and, in one case, tonic/clonic seizures,
associated with seroconversion to HIV [29]. Another report described an acutely infected patient with signs
of both encephalopathy and myelopathy, including lower extremity spasticity, bilateral extensor plantar
reflexes, and urinary retention, which progressed to upper extremity spasticity and weakness [30].

The peripheral nervous system also may be affected by acute HIV infection. As an example, one report
described two cases of Guillain-Barré syndrome occurring 1 and 20 weeks after symptomatic acute HIV
[31]. Facial nerve and brachial palsies have also been noted [23,32,33].

Other — Apart from complaints of a dry cough, pulmonary manifestations are uncommon during acute
HIV infection. There have been rare reports of pneumonitis in this setting, manifesting as cough, dyspnea,
and hypoxia without evidence for other infectious etiologies [34,35]. Two of these patients had increased
interstitial markings on chest radiograph. Bronchoalveolar lavage was performed in one patient and
revealed a predominance of CD8+ lymphocytes.

Acute rhabdomyolysis and vasculitis are other unusual manifestations [36,37]. (See "Overview of viral
myositis".)

Opportunistic infections — Although usually associated with later stage HIV disease, opportunistic
infections can rarely occur during the transient CD4 lymphopenia of early HIV infection [38]. In a study of
290 patients who were diagnosed with acute or early HIV infection at a single center over 10 years, 21
presented with an opportunistic illness [7].

Oral and esophageal candidiasis is the opportunistic infection most often seen in these patients [7,39,40].
The factors responsible for the frequency of esophageal candidiasis during the immunosuppression of acute
HIV infection are not well understood [41]. Two possibilities are that esophageal ulceration provides a local
environment that promotes the growth of Candida species, and that the administration of antibiotics to
empirically treat the symptoms of acute HIV may alter normal oropharyngeal flora.

Other opportunistic infections that have been reported during acute HIV infection include CMV infection
(proctitis, colitis, and hepatitis) [7,25], Pneumocystis jirovecii pneumonia [42], and prolonged, severe
cryptosporidiosis [43].

Laboratory features — In early HIV infection, which is a period of rapid viral replication and infection of
CD4 T cells, the viral RNA level is typically very high (eg, >100,000 copies/mL) and the CD4 cell count can
drop transiently. (See 'HIV RNA detection' below and 'Opportunistic infections' above.)
As an example, in a study of 50 acutely infected individuals, the median peak viral level was approximately
5 million copies/mL and occurred at a median of 13 days (range 6 to 18) following initial detection of viral
RNA [2]. Subsequently, the viral load dropped to a median of 30,000 copies/mL between 18 and 42 days
following RNA detection and remained generally stable within one log over the following year.

The leukocyte count and lymphocyte subset counts vary during the acute illness. Initially, there is a fall in the
total white blood cell count. In one study, for example, the leukocyte count dropped to a low of 960/microL
nine days after the onset of symptoms [44]. CD4 cell counts drop in relation to the increase in viral load, and
CD8 cell counts increase. Following peak viremia, CD4 cell counts rebound and CD8 cell counts decline,
but do not generally return to baseline levels. CD8 cell levels remain higher than CD4 cell levels, resulting in
a persistent inversion of the normal CD4:CD8 ratio to less than 1 [44]. Atypical lymphocytes may be seen
during this latter phase although at a frequency and intensity significantly less than in the classic
mononucleosis syndrome caused by Epstein-Barr virus (EBV) (<50 percent versus 90 percent of cases).

A positive heterophile antibody test has also been reported uncommonly during acute HIV [15,17,19];
whether this represents a false positive test or reactivation of EBV during acute HIV is not clear [45].
Regardless of the cause, the importance of this finding is that a positive heterophile antibody test does not
exclude the diagnosis of acute HIV infection.

Additionally, elevations of liver enzymes, mild anemia, and thrombocytopenia have all been reported in
association with early HIV infection.

DIFFERENTIAL DIAGNOSIS — The differential diagnosis of acute HIV infection includes mononucleosis
due to Epstein-Barr virus (EBV) or cytomegalovirus (CMV), toxoplasmosis, rubella, syphilis, disseminated
gonococcal infection, viral hepatitis, and other viral infections. Certain features of new onset autoimmune
diseases may also resemble the acute retroviral syndrome. A number of clinical findings help distinguish
these disorders from acute HIV:

● Mucocutaneous ulceration is unusual in these other infections with the exception of syphilis and, if
present, should heighten suspicion for acute HIV.

● Rash is uncommon in EBV mononucleosis (unless antibiotics have been administered), CMV
mononucleosis, and toxoplasmosis and tends to spare the palms and soles in rubella. The rash of
acute HIV infection may resemble pityriasis rosea, but marked constitutional symptoms are unusual in
pityriasis [19].

● The abrupt onset of symptoms, pharyngeal edema with little associated tonsillar exudate or
hypertrophy, and diarrhea, which can be seen in acute HIV, are features that help to distinguish it from
EBV mononucleosis. Both atypical lymphocytosis and a positive heterophile antibody test can occur in
the setting of acute HIV; thus, these findings do not exclude the possibility of HIV. However, the number
of atypical lymphocytes present is generally higher in EBV than HIV.

● New onset systemic lupus erythematosus (SLE) can closely resemble acute HIV infection. However,
SLE is distinguished by the presence of antinuclear antibodies.

Symptoms associated with the acute retroviral syndrome have also been observed in patients with chronic
HIV infection who discontinued effective antiretroviral therapy [46,47]. In these case reports, symptoms
including fever, lymphadenopathy, and rash developed in four patients 10 days to four weeks after
discontinuing all antiretroviral drugs. HIV viral levels, which had been <50 copies/mL in all of the patients,
rose dramatically to as high as 1,000,000 copies/mL, and CD4 counts dropped appreciably. Cases of
recrudescent symptomatic acute HIV have also been reported in patients treated during acute infection who
have stopped treatment [48]. These situations are easily distinguished from the acute retroviral syndrome of
acute HIV infection by history.

DIAGNOSIS — The diagnosis of acute or early HIV infection is established by the detection of HIV viremia
in the setting of a particular HIV testing pattern (ie, negative screening immunoassay OR a positive
combination antibody/antigen immunoassay with a negative antibody-only immunoassay). However,
because of the increasing sensitivity of available immunoassays, an individual with acute or early HIV
infection (ie, infected within the prior six months) may already have completely reactive immunoassays (eg,
both the combination antibody/antigen immunoassay and the antibody-only immunoassay) in addition to
detectable viremia. In such cases, the timing of infection, and thus the diagnosis of acute or early versus
established infection, must be inferred from clinical presentation (eg, symptoms consistent with acute
retroviral syndrome at presentation or recognized in hindsight or a very high viral RNA level), exposure
history, and any available past serological testing.

When the possibility of acute or early HIV infection is being considered based on clinical suspicion (see
'Clinical suspicion' below), we perform the most sensitive immunoassay available (ideally, a combination
antigen/antibody immunoassay) in addition to an HIV virologic (viral load) test. (See 'Diagnostic algorithm'
below.)

Because of the increasing availability of HIV screening tests that significantly shorten the time from HIV
acquisition to a positive test and recommendations to use specific screening algorithms that are more
sensitive for early infection [49], more patients with acute or early HIV are being diagnosed on routine
screening. (See 'Detection of early infection through routine screening' below and "Screening and diagnostic
testing for HIV infection", section on 'Testing algorithm'.)

Given the increasing data supporting individual and public health benefits for antiretroviral therapy during
acute and early infection instead of later in the course of the disease, newly-diagnosed patients should be
referred promptly to an appropriate specialist to review treatment options. (See "Acute and early HIV
infection: Treatment", section on 'Rationale for initiation of ART in early infection'.)

Clinical suspicion — Given the wide range of symptoms associated with acute HIV infection, clinicians
should have a low threshold to suspect it. In particular, the possibility of acute HIV infection should be
considered in patients who present with the more typical signs and symptoms, including an ill-defined febrile
illness, heterophile-negative mononucleosis-like syndrome, heterophile positive mononucleosis in an
unusual host (for example, an older adult patient), and/or aseptic meningitis. Certain clinical features, such
as a rash, mucocutaneous ulcers, diarrhea, or lymphadenopathy, should heighten the suspicion for HIV
infection. (See 'Clinical features' above.)

Although all patients should be questioned about HIV risk behaviors, including sexual activity and injection
drug use, patients may be reluctant to disclose this information or may not perceive their behavior as high
risk. As an example, we have seen several men who acquired HIV through receptive oral sex and
expressed surprise that this was a mode of HIV transmission (see "Management of nonoccupational
exposures to HIV and hepatitis B and C in adults", section on 'Exposure to HIV'). Thus, the absence of
elicited risk factors should not preclude the possibility of HIV infection.

Early HIV infection should also be considered in patients who have had a recent high-risk exposure or those
who have had a recent sexually transmitted infection (particularly syphilis), regardless of the presence of
symptoms or signs. Certain patients who have had a very recent high-risk exposure (ie, within 72 hours)
may be candidates for post-exposure prophylaxis (PEP) against HIV. The evaluation and management of
such patients are discussed in detail elsewhere. (See "Management of nonoccupational exposures to HIV
and hepatitis B and C in adults" and "Management of health care personnel exposed to HIV".)
Diagnostic algorithm — When the possibility of acute or early HIV infection is being considered, we
perform the most sensitive screening immunoassay available (ideally, a combination antigen/antibody
immunoassay) in addition to an HIV virologic (viral load) test. We favor using an RT-PCR based viral load
test, if available. A positive HIV virologic test is generally indicative of HIV infection. The approximate timing
of infection (ie, early versus established) can be assessed by the pattern of immunoassay reactivity and the
clinical presentation (table 2):

● A negative HIV screening immunoassay and negative virologic test strongly suggests that HIV infection
has not been acquired. In the case of very recent high-risk exposures when HIV transmission remains a
concern, repeat testing in one to two weeks (especially if symptoms of acute HIV develop) is warranted.
(See 'Very recent exposure' below.)

● A negative HIV screening immunoassay and a positive virologic test suggest early HIV infection. In this
situation, however, an RNA level <1000 copies/mL may rarely represent a false positive viral test and
the viral load test should be immediately repeated on a new blood specimen. A second positive
virologic test suggests HIV infection, which a repeat serologic test several weeks later to evaluate for
seroconversion can confirm. (See 'HIV RNA detection' below.)

● A positive HIV screening immunoassay and positive virologic test can be seen in either early or
established HIV infection. A positive screening immunoassay should prompt a second, antibody-only
immunoassay (preferably the HIV-1/HIV-2 differentiation immunoassay) if not already performed. A
negative result on this second test with a positive virologic test supports the diagnosis of acute HIV
infection. However, a positive result on the second immunoassay does not exclude the possibility of
recent infection and seroconversion. In such cases, the distinction between early and established
infection must be inferred from clinical presentation (eg, symptoms consistent with acute retroviral
syndrome at presentation or recognized in hindsight or a very high viral RNA level), exposure history,
and any available past serological testing (eg, a negative serological test within the prior six months).

If the diagnosis of acute or early HIV infection was based on a single positive virologic test in the setting of a
negative HIV immunoassay, it is appropriate to confirm the diagnosis of acute or early HIV with a second
test. This may be a repeat HIV RNA or serologic test in several weeks to document seroconversion. If
treatment is started, it need not await the confirmatory testing unless the initial diagnosis is uncertain.

This diagnostic algorithm for suspected acute HIV infection is distinct from general screening algorithms that
include an immunoassay followed by a confirmatory immunoassay of a second type if the first is positive,
with HIV RNA testing reserved for discrepant results between the two immunoassays. The major difference
is the use of the virologic test at the same time as the screening immunoassay. (See 'Detection of early
infection through routine screening' below and "Screening and diagnostic testing for HIV infection".)

Detection of early infection through routine screening — Since many guidelines now recommend
universal screening for HIV infection, new HIV diagnoses, including those of early infection, may be made
among patients in whom HIV infection was not initially suspected.

In the United States, the recommended algorithm for screening involves an initial fourth generation
combined antigen/antibody immunoassay with a confirmatory antibody-only HIV-1/HIV-2 differentiation
immunoassay followed by HIV viral testing if there is a discrepancy (algorithm 1) [49]. In this algorithm,
acute or early HIV is diagnosed when the initial immunoassay is reactive, the second immunoassay is
nonreactive, and the viral test detects HIV RNA repeatedly or at a high level. (See "Screening and
diagnostic testing for HIV infection", section on 'Testing algorithm'.)

This algorithm is more sensitive for detecting acute and early HIV infection than the previous algorithm,
which involved following a reactive screening immunoassay with a Western blot test. As an example, in a
study of 99 patients who had a reactive combination antibody and antigen immunoassay on screening
followed by a nonreactive second immunoassay, RNA testing was positive in 55 individuals, thus making the
diagnosis of early infection [50]. Of these patients with early infection, 27 also underwent Western blot
testing, of whom 15 (56 percent) had a negative test and thus may have otherwise had missed diagnoses.

Of note, while this algorithm is more likely to detect some cases of early HIV infection during routine
screening, if acute or early HIV infection is suspected (eg, based on the presence of symptoms or recent
exposures), we continue to favor performing a sensitive immunoassay and virologic test at the same time.
(See 'Diagnostic algorithm' above.)

Some laboratories may still employ Western blot testing to confirm an initial reactive immunoassay.
Detecting early HIV with this algorithm requires checking a viral RNA test if the Western blot is negative or
indeterminate. In such cases, a reactive immunoassay followed by a negative or indeterminate Western blot
followed by a positive viral RNA test is most likely indicative of early HIV infection. Thus, a reactive
immunoassay followed by a negative or indeterminate Western blot should not be erroneously interpreted
as a negative screening pattern for HIV without further testing.

Clinical relevance of early detection — Diagnosis of acute HIV is important, since prompt initiation of ART
reduces the likelihood of HIV transmission to others and can reduce the size of the latent HIV reservoir,
potentially making patients eligible for future HIV eradication strategies. Early ART also can improve
symptoms related to acute HIV infection. This is discussed in detail elsewhere. (See "Acute and early HIV
infection: Treatment", section on 'Rationale for initiation of ART in early infection'.)

Considerations for specific populations

Very recent exposure — Detectable viremia does not develop until approximately 10 to 15 days after
infection, and even the most sensitive immunoassays do not become positive until five days after that (table
2). Thus, if exposure occurred during this window, the diagnosis of HIV infection may be missed. If initial
immunoassay and virologic tests are negative and clinical suspicion for recent HIV exposure is high, we
repeat testing one to two weeks later.

Diagnostic test performance in early HIV infection

HIV RNA detection — Early HIV infection is characterized by markedly elevated HIV RNA levels, easily
detectable with the HIV RNA (viral load) assays commonly used for monitoring of HIV disease. Our
preferred test for HIV RNA detection in the evaluation for early HIV infection is the reverse transcriptase-
polymerase chain reaction (RT-PCR) test because of its superior performance to the branch DNA (bDNA)
technique. Although not approved by the US Food and Drug Administration (FDA) for this indication, the RT-
PCR test is widely available for HIV disease monitoring and is highly sensitive and specific. A false positive
test should be ruled out if the viral load is low (<1000 copies/mL) in the setting of suspected early HIV
infection [51,52]. A repeat sample should be drawn in this setting since a second positive viral load
(especially if higher) suggests a true positive result [53], as would subsequent seroconversion.

In a study of 436 patients with symptoms consistent with acute HIV infection, all of the 54 patients
diagnosed with acute HIV had RNA levels >100,000 copies/mL [6]. Although false-positive detection of HIV
RNA occurred in 8 of 303 (2.6 percent) patients without HIV infection, all of the false-positives had HIV RNA
levels <2000 copies/mL, making them easily distinguishable from the true positives whose values were
much higher. Furthermore, all of the false positives occurred with bDNA rather than RT-PCR viral load
testing; bDNA testing has subsequently become less widely used. In a separate study of 258 symptomatic
patients evaluated for acute HIV infection, RT-PCR based testing also had a lower false positive rate than
bDNA tests (3 versus 5 percent) [54]. (See "Techniques and interpretation of HIV-1 RNA quantitation",
section on 'Laboratory methods for quantitation of HIV-1 RNA'.)

A qualitative nucleic acid test (NAT) based on transcription mediated amplification is an additional sensitive
method to detect acute HIV viremia in patients who are antibody-negative [55,56]. The main utility of NAT is
for large population screening (such as blood donor screening), which is generally performed on pooled
specimens because of the cost of the test.

HIV antigen detection — The p24 antigen is a viral core protein that appears in the blood as the viral
RNA level rises following HIV infection [57,58]. Although earlier assays to detect p24 antigen were
considerably less sensitive than viral RNA testing, subsequent assays have better diagnostic performance,
with a sensitivity range of 89 to nearly 100 percent compared to RNA detection [59,60]. This assay detects a
level of antigen that approximately corresponds to an HIV RNA level of 30,000 to 50,000 copies/mL and
becomes positive approximately five to seven days following the detection of viral RNA [61-63].

The p24 antigen test is also available as combination HIV antibody/p24 antigen tests that turn positive with
detection of either the antigen or the antibody and shortens the window period between HIV acquisition and
a positive test compared with antibody only tests. Nevertheless, combination immunoassays remain less
sensitive than nucleic acid based tests for acute HIV infection in clinical settings [64,65]. As an example, in a
study comparing a fourth generation combination test (Architect) with pooled HIV RNA testing among 134
patients with acute HIV infection, both were highly specific and the combination test was less costly, but it
was also less sensitive (80 versus 98 percent with pooled RNA testing) [65]. This highlights the importance
of HIV viral level testing when acute or early infection is suspected. (See 'Diagnostic algorithm' above.)

Rapid combination antigen/antibody tests do not appear to be quite as sensitive as the standard
combination test used in laboratories [66]. (See "Screening and diagnostic testing for HIV infection", section
on 'Combination HIV antigen and antibody tests'.)

Serologic studies — After infection with HIV, the time at which antibodies against HIV antigens can be
detected in the serum depends upon the sensitivity of the serologic test (table 2). Thus, depending on the
time since infection and the sensitivity of the immunoassay test used, patients with acute or early HIV
infection may have either a negative or reactive immunoassay. (See "Screening and diagnostic testing for
HIV infection".)

Very early treatment for acute HIV infection can lead to abrogation of HIV antibody responses [67,68]. As an
example, in a study of 150 patients with acute HIV infection treated with antiretroviral therapy (ART), three
patients did not develop a fully evolved antibody response and/or demonstrated evidence of seroreversion
after successful HIV RNA suppression [67]. It has been postulated that maturation of the antibody response
can be thwarted by rapid HIV RNA suppression early in the course of disease [69]. It is critical that clinicians
and patients understand that seroreversion does not indicate viral eradication [68,70].

ADDITIONAL EVALUATION

Drug resistance testing — For all patients with early HIV infection, drug resistance testing should be
performed after the initial diagnosis has been established, regardless of whether treatment is being
considered [1,71]. In studies of patients with acute and early HIV infection, about 15 to 20 percent of
patients were infected with an isolate harboring at least one drug resistance mutation [72-74]. The presence
of mutations in transmitted strains is strongly influenced by antiretroviral drug use patterns in the source.
Mutations conferring resistance to non-nucleoside reverse transcriptase inhibitors are more common than
protease inhibitor resistance mutations. (See "Acute and early HIV infection: Pathogenesis and
epidemiology".)
In this setting, genotype resistance testing is preferred over phenotype testing because of its lower cost,
faster turnaround time (approximately one versus three to four weeks), and its greater sensitivity for
mixtures of resistant and wild-type virus. The interpretation of results of resistance testing is discussed in
detail elsewhere. (See "Overview of HIV drug resistance testing assays" and "Interpretation of HIV drug
resistance testing".)

If initiation of HIV therapy is ultimately decided upon, selection of treatment regimens should take into
consideration these initially detected resistance mutations. Determination of the patient's drug resistance
profile soon after infection is important since some resistance mutations may become undetectable over
time without the selection pressure of antiretroviral therapy. As an example, in a study of men recently
infected with HIV that harbored mutations that conferred resistance against non-nucleoside reverse
transcriptase inhibitors, the two men followed beyond one year were noted to have experienced reversion of
mutations to wild-type virus after 2.5 to 3.5 years [75]. Moreover, despite the loss of drug resistance
mutations in circulating virus, resistance mutations were still detected in virus present in the semen.

Screening for coinfections and prior exposures — All patients with newly diagnosed HIV infection
should also undergo testing for other sexually transmitted infections. (See "Screening for sexually
transmitted infections", section on 'HIV-infected patients'.)

Evaluation for exposure to other chronic infections, as performed in patients diagnosed with chronic HIV
infection, is also indicated to establish the risk of possible future reactivation or need for vaccination. (See
"Initial evaluation of the HIV-infected adult", section on 'Screening for co-infections' and "Initial evaluation of
the HIV-infected adult", section on 'Sexually transmitted infections'.)

PUBLIC HEALTH IMPLICATIONS — Establishing the diagnosis of early HIV infection is clearly important
from the public health perspective. Patients are typically highly infectious during early HIV due to an
enormous viral burden in blood and genital secretions (with a general range of serum RNA levels 100,000 to
greater than one million copies/mL compared with 30,000 to 50,000 copies/mL in chronic infection without
treatment) [76-78]. Moreover, such patients may be unaware that they are infected and continue to engage
in risky sexual activity and needle sharing, putting others at risk. In one analysis of recently infected men
who have sex with men (MSM), the rate of transmission during early infection was 9 to 15-fold greater than
the transmission risk during chronic infection [79]. Similarly, in some settings, transmission from acutely
infected individuals is estimated to account for the majority of new HIV infections [80-82]. Pregnant women
who are unaware of their acute infection can transmit HIV perinatally unless a timely diagnosis is made and
antiretroviral therapy is initiated [83].

Nevertheless, the diagnosis of acute or early HIV infection is infrequently made in clinical practice. In a case
series from Seattle, for example, the diagnosis of HIV infection was considered in only 5 of 19 patients (26
percent) with acute retroviral syndrome who sought care from their primary care clinicians, emergency
departments, and walk-in clinics [16]. This finding was especially surprising since these patients were
enrolled in a surveillance program for HIV.

There are several reasons why acute and early HIV infection is so infrequently diagnosed:

● The symptoms, especially in mild cases, are nonspecific and resolve spontaneously without treatment.
Also, many patients may be asymptomatic. (See 'Clinical features' above.)

● Clinicians may be uncomfortable asking questions about sexual exposure or intravenous drug use,
especially with patients whom they see infrequently, such as young, previously healthy individuals.

● Primary care clinicians may not be aware of high-risk behavior even in patients they know well. Such
patients often choose to undergo counseling and serial serologic testing at an anonymous clinic rather
 than to discuss risk behaviors with their primary care provider.

● Patients may not perceive themselves to be at risk.

● Clinicians and patients may assume continued validity of a previously negative HIV test, even in high-
risk patients.

These issues highlight the importance of maintaining a high degree of suspicion in considering the
possibility of acute HIV infection in patients with ill-defined febrile illnesses regardless of apparent risk
factors. (See 'Clinical suspicion' above.)

All patients with suspected or confirmed acute or early HIV infection should be counseled to adopt behaviors
that guard against HIV transmission, including consistent and correct condom use and avoidance of sharing
injection drug use equipment.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected
countries and regions around the world are provided separately. (See "Society guideline links: HIV
screening and diagnostic testing".)

SUMMARY AND RECOMMENDATIONS

● In this topic, we use the term "early HIV infection" to refer to the approximate six-month period following
HIV acquisition. We use the term "acute HIV infection" to refer to symptomatic early infection. (See
'Definitions' above.)

● A variety of symptoms and signs may be seen in association with acute HIV infection, known as the
acute retroviral syndrome. The most common findings are fever, lymphadenopathy, sore throat, rash,
myalgia/arthralgia, and headache. When it occurs, painful mucocutaneous ulceration is one of the most
distinctive manifestations of acute HIV infection. Aseptic meningitis has also been reported. Some
patients with early HIV infection may have no or only very mild symptoms (table 1). (See 'Clinical
features' above.)

● In early HIV infection, the viral RNA level is typically very high (eg, >100,000 copies/mL) and the CD4
cell count can drop transiently. Opportunistic infections can rarely occur during this transient CD4
lymphopenia. (See 'Laboratory features' above and 'Opportunistic infections' above.)

● The differential diagnosis of acute HIV infection includes mononucleosis due to Epstein-Barr virus
(EBV) or cytomegalovirus (CMV), toxoplasmosis, rubella, syphilis, viral hepatitis, disseminated
gonococcal infection, and other viral infections. Certain features of new onset autoimmune diseases
may also resemble the acute retroviral syndrome. (See 'Differential diagnosis' above.)

● The diagnosis of acute HIV infection requires a high level of clinical suspicion and should be considered
in patients who present with consistent signs and symptoms, including an ill-defined febrile illness,
heterophile-negative mononucleosis-like syndrome, and/or aseptic meningitis. Early HIV infection
should also be considered in patients who have had a recent high-risk exposure or those who have had
a recent sexually transmitted infection (particularly syphilis), regardless of the presence of symptoms or
signs. (See 'Clinical suspicion' above.)

● Diagnosis of acute HIV is important, since prompt initiation of antiretroviral therapy reduces the
likelihood of HIV transmission to others and can reduce the size of the latent HIV reservoir, potentially
making patients eligible for future HIV eradication strategies. (See "Acute and early HIV infection:
Treatment", section on 'Rationale for initiation of ART in early infection'.)
● When the possibility of acute or early HIV infection is being considered, we perform the most sensitive
immunoassay available (ideally, a combination antigen/antibody immunoassay) in addition to an HIV
virologic (viral load) test. A positive virologic test indicates HIV infection. Acute or early HIV infection is
indicated if the initial immunoassay is negative OR if a combination antigen/antibody immunoassay is
positive but a second antibody-only immunoassay is negative.(See 'Diagnostic algorithm' above.)

● Because of the increasing sensitivity of immunoassays, some patients infected with HIV within the
previous six months will have already undergone seroconversion and thus have completely reactive
immunoassays (eg, both the combination antibody/antigen immunoassay and the antibody-only
immunoassay) and a positive virologic test (table 2). In these situations, the timing of infection and thus
the diagnosis of early HIV infection can be presumptively made on the basis of clinical presentation (eg,
earlier symptoms consistent with acute retroviral syndrome recognized in hindsight or a very high viral
RNA level), exposure history, and any available past serological testing. (See 'Diagnostic algorithm'
above.)

● A viral RNA level <1000 copies/mL in a patient with a negative serologic test may represent a false
positive viral test, as patients with acute or early HIV infection typically have very high levels of viremia.
The virologic test should be immediately repeated on a new blood specimen. A second positive
virologic test suggests HIV infection, which a repeat serologic test several weeks later to evaluate for
seroconversion can confirm. (See 'Diagnostic algorithm' above.)

● With the widespread availability of HIV screening tests that significantly shorten the time from HIV
acquisition to a positive test, more patients with acute or early HIV infection are being diagnosed on
routine screening. (See 'Detection of early infection through routine screening' above.)

● Drug-resistant testing should be performed after the initial diagnosis of HIV infection, as infection with a
virus that harbors at least one drug resistance mutation is estimated to occur in up to 20 percent of
newly infected patients. (See 'Additional evaluation' above.)

● All patients with suspected or confirmed acute or early HIV infection should be counseled to adopt
behaviors that guard against HIV transmission, including consistent and correct condom use and
avoidance of sharing injection drug use equipment. (See 'Public health implications' above.)

● Given the increasing data supporting individual and public health benefits for antiretroviral therapy
during acute and early infection instead of later in the course of the disease, newly-diagnosed patients
should be referred promptly to an appropriate specialist to review treatment options. (See "Acute and
early HIV infection: Treatment", section on 'Rationale for initiation of ART in early infection'.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral a
gents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available
at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on May 01, 20
14).
2. Robb ML, Eller LA, Kibuuka H, et al. Prospective Study of Acute HIV-1 Infection in Adults in East
Africa and Thailand. N Engl J Med 2016; 374:2120.
3. Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency
virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336:919.
 4. Kared H, Lelièvre JD, Donkova-Petrini V, et al. HIV-specific regulatory T cells are associated with
higher CD4 cell counts in primary infection. AIDS 2008; 22:2451.
5. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of
pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis
1993; 168:1490.
6. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV
Infection Recruitment Network. Ann Intern Med 2001; 134:25.
7. Braun DL, Kouyos RD, Balmer B, et al. Frequency and Spectrum of Unexpected Clinical
Manifestations of Primary HIV-1 Infection. Clin Infect Dis 2015; 61:1013.
8. Crowell TA, Colby DJ, Pinyakorn S, et al. Acute Retroviral Syndrome Is Associated With High Viral
Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. Clin Infect Dis
2018; 66:1540.
9. Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr
Opin HIV AIDS 2008; 3:10.
10. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point
in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445.
11. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV
type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis
2006; 42:1333.
12. McKellar MS, Cope AB, Gay CL, et al. Acute HIV-1 infection in the Southeastern United States: a
cohort study. AIDS Res Hum Retroviruses 2013; 29:121.
13. Quinn TC. Acute primary HIV infection. JAMA 1997; 278:58.
14. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences
for subsequent course of infection. BMJ 1989; 299:154.
15. Gaines H, von Sydow M, Pehrson PO, Lundbegh P. Clinical picture of primary HIV infection presenting
as a glandular-fever-like illness. BMJ 1988; 297:1363.
16. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection.
Ann Intern Med 1996; 125:257.
17. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS 1991;
5:1.
18. Valle SL. Febrile pharyngitis as the primary sign of HIV infection in a cluster of cases linked by sexual
contact. Scand J Infect Dis 1987; 19:13.
19. de Jong MD, Hulsebosch HJ, Lange JM. Clinical, virological and immunological features of primary
HIV-1 infection. Genitourin Med 1991; 67:367.
20. Lapins J, Gaines H, Lindbäck S, et al. Skin and mucosal characteristics of symptomatic primary HIV-1
infection. AIDS Patient Care STDS 1997; 11:67.
21. Stamm WE, Handsfield HH, Rompalo AM, et al. The association between genital ulcer disease and
acquisition of HIV infection in homosexual men. JAMA 1988; 260:1429.
22. Rabeneck L, Popovic M, Gartner S, et al. Acute HIV infection presenting with painful swallowing and
esophageal ulcers. JAMA 1990; 263:2318.
23. Calabrese LH, Proffitt MR, Levin KH, et al. Acute infection with the human immunodeficiency virus
(HIV) associated with acute brachial neuritis and exanthematous rash. Ann Intern Med 1987; 107:849.
24. Rizzardi GP, Tambussi G, Lazzarin A. Acute pancreatitis during primary HIV-1 infection. N Engl J Med
1997; 336:1836.
25. Molina JM, Welker Y, Ferchal F, et al. Hepatitis associated with primary HIV infection.
Gastroenterology 1992; 102:739.
26. Meersseman W, Van Laethem K, Lagrou K, et al. Fatal brain necrosis in primary HIV infection. Lancet
2005; 366:866.
27. Ho DD, Sarngadharan MG, Resnick L, et al. Primary human T-lymphotropic virus type III infection. Ann
Intern Med 1985; 103:880.
28. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of
patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med
1985; 313:1493.
29. Carne CA, Tedder RS, Smith A, et al. Acute encephalopathy coincident with seroconversion for anti-
HTLV-III. Lancet 1985; 2:1206.
30. Denning DW, Anderson J, Rudge P, Smith H. Acute myelopathy associated with primary infection with
human immunodeficiency virus. Br Med J (Clin Res Ed) 1987; 294:143.
31. Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barré syndrome as an early manifestation of
HIV central nervous system infection. Scand J Infect Dis 1986; 18:591.
32. Parry GJ. Peripheral neuropathies associated with human immunodeficiency virus infection. Ann
Neurol 1988; 23 Suppl:S49.
33. Piette AM, Tusseau F, Vignon D, et al. Acute neuropathy coincident with seroconversion for anti-
LAV/HTLV-III. Lancet 1986; 1:852.
34. Ong EL, Mandal BK. Primary HIV-I infection associated with pneumonitis. Postgrad Med J 1991;
67:579.
35. Longworth DL, Spech TJ, Ahmad M, et al. Lymphocytic alveolitis in primary HIV infection. Cleve Clin J
Med 1990; 57:379.
36. Mahé A, Bruet A, Chabin E, Fendler JP. Acute rhabdomyolysis coincident with primary HIV-1 infection.
Lancet 1989; 2:1454.
37. Bernard E, Dellamonica P, Michiels JF, et al. Heparine-like anticoagulant vasculitis associated with
severe primary infection by HIV. AIDS 1990; 4:932.
38. Gupta KK. Acute immunosuppression with HIV seroconversion. N Engl J Med 1993; 328:288.
39. Cilla G, Perez Trallero E, Furundarena JR, et al. Esophageal candidiasis and immunodeficiency
associated with acute HIV infection. AIDS 1988; 2:399.
40. Isaksson B, Albert J, Chiodi F, et al. AIDS two months after primary human immunodeficiency virus
infection. J Infect Dis 1988; 158:866.
41. Tindall B, Hing M, Edwards P, et al. Severe clinical manifestations of primary HIV infection. AIDS 1989;
3:747.
42. Vento S, Di Perri G, Garofano T, et al. Pneumocystis carinii pneumonia during primary HIV-1 infection.
Lancet 1993; 342:24.
43. Moss PJ, Read RC, Kudesia G, McKendrick MW. Prolonged cryptosporidiosis during primary HIV
infection. J Infect 1995; 30:51.
44. Cooper DA, Tindall B, Wilson EJ, et al. Characterization of T lymphocyte responses during primary
infection with human immunodeficiency virus. J Infect Dis 1988; 157:889.
45. Vidrih JA, Walensky RP, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests
in patients with primary human immunodeficiency virus infection. Am J Med 2001; 111:192.
46. Colven R, Harrington RD, Spach DH, et al. Retroviral rebound syndrome after cessation of
suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000;
 133:430.
47. Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of
antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med 2000;
133:435.
48. Daar ES, Bai J, Hausner MA, et al. Acute HIV syndrome after discontinuation of antiretroviral therapy
in a patient treated before seroconversion. Ann Intern Med 1998; 128:827.
49. http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf (Accessed on June 30, 201
4).
50. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations
of a new HIV diagnostic testing algorithm - United States, 2011-2013. MMWR Morb Mortal Wkly Rep
2013; 62:489.
51. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load
testing: a case series. Ann Intern Med 1999; 130:37.
52. Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, et al. Extensive evaluation of a seronegative
participant in an HIV-1 vaccine trial as a result of false-positive PCR. Lancet 1997; 350:256.
53. Stekler J, Maenza J, Stevens CE, et al. Screening for acute HIV infection: lessons learned. Clin Infect
Dis 2007; 44:459.
54. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of
primary HIV infection. AIDS 2002; 16:1119.
55. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North
Carolina. N Engl J Med 2005; 352:1873.
56. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using
3 different screening immunoassays and nucleic acid amplification testing for human
immunodeficiency virus RNA, 2006-2008. Arch Intern Med 2010; 170:66.
57. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis 2010; 202
Suppl 2:S270.
58. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in
plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871.
59. Pandori MW, Hackett J Jr, Louie B, et al. Assessment of the ability of a fourth-generation
immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute
and recent HIV infections in a high-risk setting. J Clin Microbiol 2009; 47:2639.
60. Chavez P, Wesolowski L, Patel P, et al. Evaluation of the performance of the Abbott ARCHITECT HIV
Ag/Ab Combo Assay. J Clin Virol 2011; 52 Suppl 1:S51.
61. Owen SM. Testing for acute HIV infection: implications for treatment as prevention. Curr Opin HIV
AIDS 2012; 7:125.
62. Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis
2012; 205:521.
63. Delaney KP, Hanson DL, Masciotra S, et al. Time Until Emergence of HIV Test Reactivity Following
Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clin
Infect Dis 2017; 64:53.
64. De Souza MS, Phanuphak N, Pinyakorn S, et al. Impact of nucleic acid testing relative to
antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS 2015;
29:793.
65. Peters PJ, Westheimer E, Cohen S, et al. Screening Yield of HIV Antigen/Antibody Combination and
Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population. JAMA 2016;
 315:682.
66. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of the
determine® HIV-1/2 Ag/Ab combo test. J Infect Dis 2012; 205:528.
67. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion
in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868.
68. Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy
during acute/early HIV infection. Clin Infect Dis 2006; 42:700.
69. Selleri M, Orchi N, Zaniratti MS, et al. Effective highly active antiretroviral therapy in patients with
primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir
Immune Defic Syndr 2007; 46:145.
70. Connick E. Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1
infection: what is the clinical significance? Clin Infect Dis 2005; 40:874.
71. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1
infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;
47:266.
72. Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs
between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258.
73. Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in
San Francisco, 2002-2009. PLoS One 2010; 5:e15510.
74. Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent
HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673.
75. Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male
genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356.
76. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human
immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961.
77. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex
virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005;
191 Suppl 1:S107.
78. Colfax GN, Buchbinder SP, Cornelisse PG, et al. Sexual risk behaviors and implications for secondary
HIV transmission during and after HIV seroconversion. AIDS 2002; 16:1529.
79. Hollingsworth TD, Pilcher CD, Hecht FM, et al. High Transmissibility During Early HIV Infection Among
Men Who Have Sex With Men-San Francisco, California. J Infect Dis 2015; 211:1757.
80. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of
HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.
81. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-
1 infection. J Infect Dis 2007; 195:951.
82. O'Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep 2012; 9:101.
83. Patterson KB, Leone PA, Fiscus SA, et al. Frequent detection of acute HIV infection in pregnant
women. AIDS 2007; 21:2303.

Topic 86984 Version 18.0